Navigation Links
Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:5/25/2010

CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The Company had previously received approval from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct the trial in those countries, respectively. Oncolytics intends to conduct the first stage of the trial at approximately 25 centres in the U.S., U.K., and Belgium but may elect to add centres in additional countries.

"Opening enrollment in our first pivotal study in an important step forward in our increasingly late stage REOLYSIN clinical program," said Dr. Brad Thompson, President and CEO of Oncolytics. "We expect enrollment to ramp up over the next quarter as additional centres come on line as the trial progresses."

As previously disclosed, the randomized, two-arm, double-blind, multicentre, two-stage, adaptive Phase 3 trial will assess the intravenous administration of REOLYSIN with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, or squamous cell cancer of the nasopharynx, who have progressed on or after prior platinum-based chemotherapy. All patients will receive treatment every three weeks (21 day cycles) with paclitaxel and carboplatin and will also receive, on a blinded basis, either intravenous placebo or
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
2. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
3. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
4. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
5. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
6. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
7. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
9. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
10. Oncolytics Biotech(R) Inc. Announces Unit Offering
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... Human Longevity, Inc. (HLI), a genomics and ... the healthy, high performance human life span, today announced ... expert in machine learning and machine translation as the ... Google where he was Distinguished Research Scientist and the ... HLI Co-Founder and CEO, J. Craig Venter , ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... ,60s cleanup of toxic pollution in Seattle,s ... Lake Washington, ... but sometimes, at least in the case of a little fish called ... study led by researchers at Fred Hutchinson Cancer Research,Center and published online ...
... KV is Now Offering The Complete Line of All Four ... ... the 50 mg ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires ...
... BALTIMORE, May 15 Lentigen Corporation announced today,that ... (NIH) small,business innovation research (SBIR) grants to collaborate ... its proprietary,lentiviral vector (LV) technology to the development ... medical need:, -- Melanoma, with Michael ...
Cached Biology Technology:Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 2Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 3Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 4KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 2KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 3KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 4Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... DURHAM, N.C. Under the microscope, the bacteria start dividing ... on. But then individual cells begin "popping," like circus balloons ... Duke University bioengineers who captured it on video, turns out ... must be considered by scientists creating living, synthetic circuits out ...
... professor Kam Tang of the Virginia Institute of Marine ... fleas" play an important role in carrying hitchhiking bacteria ... article, "Bacteria dispersal by hitchhiking on zooplankton," appeared in ... the National Academy of Sciences . It was co-authored ...
... - Greenhouse gas markets, where invisible gases are ... people. Farmers can make money on these markets, ... methane capture technologies in animal-based systems, no-till farming, ... extension educators, offset aggregators, and other stakeholders need ...
Cached Biology News:Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3Study shows that hitchhiking bacteria can go against the flow 2Study shows that hitchhiking bacteria can go against the flow 3Greenhouse gas calculator connects farming practices with carbon credits 2